Key Highlights

  • On November 3, 2025, Kyverna drew $25.0 million from the initial Term A tranche.
  • Term C loans are structured as two tranches of $20.0 million each, tied to revenue and clinical milestones.
  • Kyverna Therapeutics, Inc. (NASDAQ: KYTX) disclosed that it has revised its $150.0 million loan agreement with Oxford Finance LLC and participating lenders.

Kyverna Therapeutics, Inc. (NASDAQ: KYTX) disclosed that it has revised its $150.0 million loan agreement with Oxford Finance LLC and participating lenders. The amendment adjusts draw schedules, introduces new fees, and links future financing to specific performance milestones.

Loan Facility Overview

The original agreement provides a non‑dilutive loan facility of up to $150.0 million, segmented into multiple tranches. Up to $40.0 million is available under the first tranche, known as Term A, while a single Term B loan ranges from $5.0 million to $20.0 million, and additional Term C financing is planned. In exchange, Kyverna must remit an upfront cash fee of $187,500.

Should the company not tap the Term B facility, a non‑utilization fee of 1.0% will apply to the undrawn balance.

Term C Structure

Term C financing is organized into two tranches of $20.0 million each. The first tranche becomes accessible upon meeting a revenue milestone, while the second tranche requires a clinical milestone. Both are slated to be available through the earlier of March 31, 2028, or 90 days after the respective milestone.

Revenue Covenant Impact

The amendment sets minimum revenue covenants that will commence in the quarter ending June 30, 2027, with alternative start dates of September 30, 2027, or December 31, 2027, based on the total cash proceeds Kyverna receives from other sources. These covenants will shape the company’s financial reporting obligations.

Financial Implications

The added fees and conditional extensions increase Kyverna’s cost of capital but preserve access to up to $150.0 million of non‑dilutive financing. Investors will monitor the company’s ability to meet clinical and revenue milestones that unlock the remaining loan capacity and avoid penalty fees.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.